ValiRx Regulatory News (VAL)

25 Oct 2007 16:00

For immediate release: VALIRX PLC ("ValiRx" or the "Company") Directorate change and directors' holdings

The Board of ValiRx (AIM: VAL) are pleased to announce that non-executive director, James Nicholas Thorniley, has been appointed non-executive Chairman with immediate effect. His appointment follows the resignation today of Anthony Moore as Chairman who has stood down from the Board to focus on other commercial interests.

Satu Vainikka, CEO of ValiRx, commented:

"Anthony has played an instrumental role in the formation of the Company, its funding and admission to AIM. Following the completion of the Company's first year on AIM after the reverse takeover, he felt the timing was right to stand down. The Board would like to thank him for his contribution to the business over the last two years."

Further to his resignation, Anthony Moore has informed the Company that he has today disposed of 100,000 ordinary shares of 6p each in the Company ("Ordinary Shares") at 12p per share, reducing his shareholding to 275,000 Ordinary Shares representing 0.87% of the issued ordinary share capital of the Company.

---ENDS---

About ValiRx plc

ValiRx is a biopharmaceutical development company that is building a portfolio of complementary cancer-related therapeutic and diagnostic technologies. It currently holds stakes in Cronos Ltd, Valibio SA and Morphogenesis Inc;

* Cronos holds licenses to two innovative and potentially market changing technologies, GeneICE and HyperGenomics; * Valibio SA is developing oncology diagnostic products based on groundbraking technologies, Hypergenomics and Nucleosomics. * Morphogenesis Inc. is developing a portfolio of cell therapy products for the treatment of chronic disorders. Its most advanced product, being ImmuneFx¢â€ž¢ for which it recently received a patent from the US patent office.

ValiRx is headquartered in London, England.

Further information can be found at www.valirx.com

Contact Details: ValiRx Plc WH Ireland GTH Communications Dr Satu Vainikka David Youngman Toby Hall / Jade Mamarbachi +44 (0) 203 008 4416 +44 (0) 161 832 2174 +44 (0) 20 7153 8035